Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAtrato Onsite Regulatory News (ROOF)

  • This share is currently suspended. It was suspended at a price of 76.40
  • There is currently no data for ROOF

Transaction Update - Sonne Solar & Recipharm

7 Sep 2022 07:00

RNS Number : 5149Y
Atrato Onsite Energy PLC
07 September 2022
 

7 September 2022

LEI: 213800IE1PPREDIIZB62

Atrato Onsite Energy plc

(the "Company" or "ROOF")

Transaction Update

 

Atrato Onsite Energy plc (LSE: ROOF), the renewables investment trust focusing on UK commercial onsite energy, today announces two transactions for a combined consideration in excess of £31m. These are expected to deliver long dated, contracted cashflows with annual inflation or fixed uplifts in line with the Company's targeted returns.

Sonne Solar

The Company has acquired 100% of the shares of Sonne Solar Ltd - a company that owns an operational portfolio and a development pipeline of behind-the-meter ("BTM") solar PV systems - from Cero Generation (an independent portfolio company of Macquarie's Green Investment Group).

The operational portfolio consists of 33MW of installed capacity across 32 rooftop and ground mount BTM assets in the UK. The offtakers are all institutional grade and the project revenues benefit from annual inflation or fixed uplifts, with a remaining average maturity of 21 years for the power purchase agreements.

The development portfolio consists of a further 33 pipeline sites that are part of a framework agreement with a single FTSE100 business.

Recipharm

The Company also announces reaching financial close on a c. 1MWp new rooftop solar project, benefitting from a 25-year power purchase agreement with a wholly owned subsidiary of Recipharm AB ("Recipharm"). The installation is expected to be commissioned before the end of 2022.

Gurpreet Gujral, Managing Director of Atrato Partners Limited, the investment adviser to the Company, said:

"We're delighted to announce these transactions. The Sonne operational assets are an immediate source of income for ROOF whilst the development portfolio provides attractive further pipeline.

The Recipharm transaction represents ROOF's first project within the pharmaceutical sector. We are delighted to be able to provide Recipharm with a new rooftop PV system that will generate long term, low cost and fully traceable green energy."

ENQUIRIES

Atrato Partners Limited

Gurpreet Gujral

Francisca Wiggins

Carcie Rogers

 

+44 (0)20 3790 8087

Alvarium Securities Limited

Mark Thompson

Eddie Nissen

Oliver Kenyon

 

+44 (0)20 7016 6711

+44 (0)20 7016 6713

+44 (0)20 7016 6704

Kaso Legg Communications

Charles Gorman

Millie Steyn

atrato@kl-communications.com

+44 (0)20 3995 6673

+44 (0)20 3995 6671

 

Notes to Editors

Atrato Onsite Energy plc (LSE: ROOF) is an investment company focused on onsite clean energy generation, providing new renewable energy capacity with 100% carbon traceability to industrial and commercial counterparties. The Company focuses on UK commercial rooftop and onsite solar, helping its corporate clients achieve net zero and reduce their energy bills. It raised £150 million in a significantly oversubscribed IPO in November 2021. ROOF provides investors with attractive capital growth and secure, index-linked income, targeting a 5% dividend yield and a total shareholder return of 8 - 10%(1). Its shares were admitted to trading on the premium segment of the Main Market of the London Stock Exchange on 23 November 2021. Atrato Partners Limited is the Company's investment adviser.

Further information is available on the Company's website, www.atratoroof.com.

(1) The target dividend and target NAV total return set out above are targets only and are not profit forecasts. There can be no assurance that these targets can or will be met. These targets have been developed based upon assumptions with respect to future business decisions and conditions that are subject to change, including the Company's execution of its investment objective and strategies, as well as growth in the sector and markets in which the Company operates. As a result, the Company's actual results may vary from the targets set out above and those variations may be material. The target dividend yield reflects the IPO price of 100 pence per ordinary share.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQFFFLIAEIRIIF
Date   Source Headline
14th Sep 202310:42 amRNSHolding(s) in Company
13th Sep 20237:00 amRNSAcquisition of 34MW Operational Rooftop portfolio
4th Sep 20237:00 amRNSNew Revolving Credit Facility
27th Jul 202312:31 pmRNSDirector Declaration
27th Jul 20237:00 amRNSDividend Declaration
12th Jul 20237:00 amRNSProject London Road update – PPA signed
28th Jun 20237:00 amRNSProject Skeeby update – PPA signed
23rd Jun 20231:17 pmRNSDirectorate Change
13th Jun 20235:37 pmRNSDirector/PDMR Shareholding
13th Jun 20237:00 amRNSInterim results to 31 March 2023
8th Jun 20234:55 pmRNSHolding(s) in Company
7th Jun 202310:00 amRNSInvestor presentation via Investor Meet Company
25th May 20237:00 amRNSOperational update and unaudited Net Asset Value
15th May 20237:00 amRNSNotice of Interim Results
21st Apr 20239:45 amRNSChange of Registered Office
19th Apr 20237:00 amRNSDividend Declaration
14th Apr 20237:00 amRNSAcquisition of 50MW North Yorkshire solar project
12th Apr 20237:00 amRNSAppointment of Director
5th Apr 20233:18 pmRNSHolding(s) in Company
31st Mar 202311:41 amRNSDirector/PDMR Shareholding
31st Mar 20237:00 amRNSDirector/PDMR Shareholding
30th Mar 20237:00 amRNSDirector/PDMR Shareholding
30th Mar 20237:00 amRNSDirector/PDMR Shareholding
24th Mar 202310:40 amRNSInvestment of £29 million into two solar projects
10th Mar 20233:07 pmRNSResult of AGM
1st Mar 202312:01 pmRNSHolding(s) in Company
17th Feb 20233:59 pmRNSUpdate on Corporate Brokers
16th Feb 20237:00 amRNSInvestment Update and New Framework Agreement
9th Feb 20231:53 pmRNSHolding(s) in Company
2nd Feb 20237:00 amRNSNotice of AGM
26th Jan 20237:00 amRNSDividend Declaration
24th Jan 20237:00 amRNSDirector/PDMR Shareholding
5th Jan 20234:56 pmRNSHolding(s) in Company
23rd Dec 20229:09 amRNSAppointment of Joint Corporate Broker
1st Dec 20225:15 pmRNSHolding(s) in Company
1st Dec 20227:00 amRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSDirector/PDMR Shareholding
30th Nov 20227:00 amRNSDirector/PDMR Shareholding
29th Nov 20227:00 amRNSFinal Results for the period ended 30 Sept 2022
24th Nov 202212:05 pmRNSHolding(s) in Company
22nd Nov 20227:00 amRNSNo impact from Electricity Generator Levy
16th Nov 20227:00 amRNSNotice of Results
11th Nov 20227:00 amRNSDividend Declaration
31st Oct 20227:00 amRNSNet Asset Value - 30 September 2022
10th Oct 20223:43 pmRNSHolding(s) in Company
10th Oct 20223:11 pmRNSHolding(s) in Company
6th Oct 20227:16 amRNSVale of Mowbray Uodate
3rd Oct 20222:33 pmRNSDirector/PDMR Shareholding
16th Sep 20225:58 pmRNSDirector/PDMR Shareholding
7th Sep 20227:00 amRNSTransaction Update - Sonne Solar & Recipharm

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.